BTN2A1/3A1-Fc-CD19scFv / Shattuck - LARVOL DELTA

Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12 (GlobeNewswire) - "Shattuck Labs...announced it will present a poster on its bispecific Gamma Delta T Cell Engager (GADLEN) platform at SITC’s 37th Annual Meeting being held November 8th – 12th, 2022, virtually and in-person in Boston."

Preclinical • Hematological Malignancies • Lymphoma • Oncology

Cutting Edge: Bispecific γδ T Cell Engager Containing Heterodimeric BTN2A1 and BTN3A1 Promotes Targeted Activation of Vγ9Vδ2 T Cells in the Presence of Costimulation by CD28 or NKG2D. (PubMed, J Immunol) - "Using a tumor cell-free assay, we demonstrated that a BTN2A1/3A1 heterodimeric fusion protein activated human Vγ9Vδ2 T cells, but only in the presence of costimulatory signal via CD28 or NK group 2 member D. Nonetheless, addition of a bispecific γδ T cell engager BTN2A1/3A1-Fc-CD19scFv alone enhanced granzyme B-mediated killing of human CD19 lymphoma cells when cocultured with Vγ9Vδ2 T cells, suggesting expression of costimulatory ligand(s) on tumor cells is sufficient to satisfy the "signal 2" requirement. These results highlight the parallels of signal 1 and signal 2 requirements in αβ and γδ T cell activation and demonstrate the utility of heterodimeric BTNs to promote targeted activation of γδ T cells."

IO biomarker • Journal • Hematological Malignancies • Immune Modulation • Inflammation • Lymphoma • Oncology • BTN2A1 • BTN3A1 • CD19 • GZMB • NKG2D

Bispecific gamma delta T cell engagers containing butyrophilin 2A1/3A1 heterodimeric fusion protein efficiently activate Vg9Vd2 T cells and promote tumor cell killing (AACR 2022) - "In addition, the CD33-targeted GADLEN alone was able to specifically kill acute myeloid leukemia cells expressing CD33 and costimulatory ligands (e.g., CD80 and CD86) in a mechanism similar to the CD19-targeted GADLEN construct. These results highlight the ability of GADLENs in promoting targeted killing of tumor cells by providing the “active” heterodimeric BTN2A1 and BTN3A1 that is critical to enhance cytotoxic killing by Vγ9Vδ2 T cells. Furthermore, this study provides mechanistic insights into BTN-mediated activation of Vγ9Vδ2 T cells and offers proof of concept for using antigen-targeted butyrophilin heterodimeric fusion proteins for the treatment of cancer."

IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • BTN2A1 • BTN3A1 • CD19 • CD28 • CD33 • CD86 • IFNG • MICA • MICB • NKG2D • TNFA

Shattuck Labs Presents Preclinical Data at the 2022 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) - "Shattuck Labs...announced preclinical data at the 2022 American Association for Cancer Research (AACR) Annual Meeting. This includes data from SL-9258 (TIGIT-Fc-LIGHT), derived from the company’s ARC® platform, and the company’s GADLEN platform....SL-9258 (TIGIT-Fc-LIGHT) combined with anti-PD(L)1 broadened anti-tumor activity of the checkpoint antibodies in aggressive CPI-resistant tumors....Butyrophilin heterodimeric fusion proteins from Shattuck’s GADLEN platform showed enhanced tumor cell killing targeting CD19 and CD20 and demonstrated preclinical proof of concept in the treatment of cancer."

Preclinical • Oncology

Shattuck Labs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights (GlobeNewswire) - "Upcoming Events: American Association for Cancer Research Annual Meeting (AACR), April 8-13...Poster presentation on the preclinical development of SL-9258; Poster presentation on the preclinical development of GADLEN compounds."

Preclinical • Oncology

Shattuck Labs to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) - "Shattuck Labs...announced that two posters have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting....The first poster will highlight preclinical data from the company’s GADLEN™ platform, while the second will highlight preclinical data from SL-9258 (TIGIT-Fc-LIGHT), derived from the company’s ARC® platform, demonstrating its ability to broaden the activity of checkpoint inhibitors through targeted myeloid cell and effector lymphocyte activation."

Preclinical • Oncology